Asian Pacific Journal of Cancer Prevention

  • 제17권3호
  • /
  • Pages.1547-1551
  • /
  • 2016
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Factors and Survival in Acute Myeloid Leukemia Cases: a Report from the Northeast of Iran

  • Allahyari, Abolghasem (Department of Internal Medicine, Imam Reza Hospital, Mashhad University of Medical Science) ;
  • Tajeri, Tarane (Islamic Azad University of Mashhad, Medicine Faculty) ;
  • Sadeghi, Masoud (Cancer Research Center, Kermanshah University of Medical Sciences)
  • 발행 : 2016.04.11
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Acute myeloid leukemia (AML) is a clonal hematopoietic disorder resulting from genetic alterations in normal hematopoietic stem cells. The aim of this study was to evaluate prognostic factors and survival of AML patients in the Northeast of Iran. Materials and Methods: This retrospective study covered 96 patients with AML referred to Emam Reza Hospital, Mashhad city, Iran, from 2009 to 2015. Age, sex, blood group, type of AML, fever, consumption of amphotericin B, cytogenetic forms and survival were analyzed. Also, WBC, hemoglobin and platelet levels were checked. Mean follow-up was 30.5 months (60.4% mortality). Survival was plotted by GraphPad Prism 5 with Log-rank test. Results: The mean age for all AML patients at diagnosis was 40.4 years (range, 17-77 years). Some 42.7% patients were aged <35 years and 40.6% were male. In all patients, 76% had fever and 50% consumed amphotericin. T(15;17)(q22;q21) had the most prevalence (37.7%) compared to other forms. Out of 92 patients, O+(30.4%) was the most common blood group and AML-M5 (28.3%) the most common subtype. There was a significant difference in survival based on WBC and consumption of amphotericin B (P<0.05). Conclusions: WBC level, fever and consumption of amphotericin B proved to be factors for survival of AML patients. The mean age for patients in Iran is lower than other areas in the World and also survival in this study was higher than in other studies.

키워드

참고문헌

  1. Alavi S, Ashraf H, Rashidi A, et al (2006). Distribution of ABO blood groups in childhood acute leukemia. Pediatr Hematol Oncol, 23, 611-7. https://doi.org/10.1080/08880010600907221
  2. Alibhai SM, Leach M, Minden MD, et al (2009). Outcomes and quality of care in acute myeloid leukemia over 40 years. Cance, 115, 2903-11. https://doi.org/10.1002/cncr.24373
  3. Ashrafi F, Shahnazari R, Samimi MA, et al (2013). Results of treatment of acute myeloid leukemia in central part of Iran. Adv Biomed Res, 2, 51. https://doi.org/10.4103/2277-9175.114194
  4. Ayremlou P, Razavi SM, Solaymani-Dodaran M, et al (2012). Demographic and prognostic factors of 455 patients with acute leukemia admitted to two referral hospitals in tehran-iran during ten years (2001-2011). Iran J Cancer Prev, 5, 157-63.
  5. Byrd JC, Lawrence D, Arthur DC, et al (1998). Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461. Clin Cancer Res, 4, 1235-41.
  6. Cohen PL, Hoyer JD, Kurtin PJ, et al (1998). Acute myeloid leukemia with minimal differentiation. A multiple parameter study. Am J Clin Pathol, 109, 32-8. https://doi.org/10.1093/ajcp/109.1.32
  7. Douer D (2003). The epidemiology of acute promyelocytic leukemia. Best Practice Rea Clinical Haematol, 16, 357-67. https://doi.org/10.1016/S1521-6926(03)00065-3
  8. Eriksson U, Seifert B, Schaffner A (2001). Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ, 322, 579-82. https://doi.org/10.1136/bmj.322.7286.579
  9. Estey E, Dohner H (2006). Acute myeloid leukaemia. Lancet, 368, 1894-907. https://doi.org/10.1016/S0140-6736(06)69780-8
  10. Ghosh S, Shinde SC, Kumaran GS, et al (2003). Haematologic and immunophenotypic profile of acute myeloid leukemia: an experience of tata memorial hospital. Indian J Cancer, 40, 71-6.
  11. Gillis S, Dann EJ, Rund D (1996). Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia. Am J Hematol, 51, 26-31. https://doi.org/10.1002/(SICI)1096-8652(199601)51:1<26::AID-AJH5>3.0.CO;2-9
  12. Girmenia C, Frustaci AM, Gentile G, et al (2012). Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica, 97, 560-7. https://doi.org/10.3324/haematol.2011.053058
  13. Hamill RJ (2013). Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs, 73, 919-34. https://doi.org/10.1007/s40265-013-0069-4
  14. Harani MS, Adil SN, Shaikh MU, et al (2005). Frequency of fab subtypes in acute myeloid leukemia patients at Aga Khan University Hospital Karachi. J Ayub Med Coll Abbottabad, 17, 26-9.
  15. Hassan K, Qureshi M, Shafi S, et al (1993). Acute myeloid leukemia-FAB classification and its correlation with clinico-haematological features. J Pak Med Assoc, 43, 200-3.
  16. Heil G, Hoelzer D, Sanz MA, et al (1997). A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood, 90, 4710-8.
  17. Juliusson G, Antunovic P, Derolf A, et al (2009). Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry. Blood, 113, 4179-87. https://doi.org/10.1182/blood-2008-07-172007
  18. Lerch E, Espeli V, Zucca E, et al (2009). Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland. Tumori, 95, 303-10. https://doi.org/10.1177/030089160909500306
  19. Mazloumi SH, Kumari P, Madhumathi DS, et al (2012). Rare and recurrent chromosomal abnormalities and their clinical relevance in pediatric acute leukemia of south Indian population. Indian J Med Paediatr Oncol, 33, 166-9. https://doi.org/10.4103/0971-5851.103144
  20. Merkel D, Filanovsky K, Gafter-Gvili A, et al (2013). Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol, 88, 130-4. https://doi.org/10.1002/ajh.23368
  21. Mrozek K (2008). Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol, 35, 365-77. https://doi.org/10.1053/j.seminoncol.2008.04.007
  22. Oran B, Weisdorf DJ (2012). Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica, 97, 1916-24. https://doi.org/10.3324/haematol.2012.066100
  23. Pedersen-Bjergaard J, Andersen MK, Johansson B (1998). Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J Clin Oncol, 16, 1897-8. https://doi.org/10.1200/JCO.1998.16.5.1897
  24. Pulsoni A, Pagano L, Latagliata R, et al (2004). Survival of elderly patients with acute myeloid leukemia. Haematologica, 89, 296-302.
  25. Sepehrizadeh Z, Mohammadi M, Emami A, et al (2014). Assessment of cytokine expression profile in acute myeloid leukemia patients before and after chemotherapy. Turk J Haematol, 31, 149-54. https://doi.org/10.4274/tjh.2012.0164
  26. Shipley JL, Butera JN (2009). Acute myelogenous leukemia. Exp Hematol, 37, 649-58. https://doi.org/10.1016/j.exphem.2009.04.002
  27. Spitzer TR, Creger RJ, Fox RM, et al (1989). Rapid infusion amphotericin B: effective and well-tolerated therapy for neutropenic fever. Pharmatherapeutica, 5, 305-11.
  28. Stone RM, O’Donnell MR, Sekeres MA (2004). Acute myeloid leukemia. Hematol Am Soc Hematol Educ Program. 2004, 98-117.
  29. Strom SS, Oum R, Elhor Gbito KY, et al (2012). De novo acute myeloid leukemia risk factors: a Texas case-control study. Cancer, 118, 4589-96. https://doi.org/10.1002/cncr.27442
  30. Vadivelu MK, Damodaran S, Solomon J, et al (2004). Distribution of ABO blood groups in acute leukaemias and lymphomas. Ann Hematol, 83, 584-7.
  31. Walter RB, Othus M, Burnett AK, et al (2013). Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood, 121, 2424-31. https://doi.org/10.1182/blood-2012-10-462440
  32. Ziaei JE (2004). High frequency of acute promyelocytic leukemia in northwest Iran. Asian Pac J Cancer Prev, 5, 188-9.